Home Cart 0 Sign in  
X

[ CAS No. 6320-51-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 6320-51-0
Chemical Structure| 6320-51-0
Chemical Structure| 6320-51-0
Structure of 6320-51-0 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 6320-51-0 ]

Related Doc. of [ 6320-51-0 ]

Alternatived Products of [ 6320-51-0 ]

Product Details of [ 6320-51-0 ]

CAS No. :6320-51-0 MDL No. :MFCD00447556
Formula : C11H9NO3S Boiling Point : -
Linear Structure Formula :- InChI Key :-
M.W : 235.26 Pubchem ID :-
Synonyms :

Calculated chemistry of [ 6320-51-0 ]

Physicochemical Properties

Num. heavy atoms : 16
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.09
Num. rotatable bonds : 2
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 65.62
TPSA : 80.7 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.19 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.71
Log Po/w (XLOGP3) : 2.17
Log Po/w (WLOGP) : 1.53
Log Po/w (MLOGP) : 0.96
Log Po/w (SILICOS-IT) : 2.21
Consensus Log Po/w : 1.72

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.81
Solubility : 0.363 mg/ml ; 0.00154 mol/l
Class : Soluble
Log S (Ali) : -3.5
Solubility : 0.0748 mg/ml ; 0.000318 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.33
Solubility : 0.11 mg/ml ; 0.000466 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 2.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.78

Safety of [ 6320-51-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 6320-51-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 6320-51-0 ]

[ 6320-51-0 ] Synthesis Path-Downstream   1~5

  • 1
  • [ 2295-31-0 ]
  • [ 123-11-5 ]
  • [ 6320-51-0 ]
YieldReaction ConditionsOperation in experiment
98% With piperidine; glacial acetic acid In toluene at 80℃; Dean-Stark; 18 Synthesis of compound 18 (5- (4-Methoxy-benzylidene) -thiazolidine-2,4-dione) Thiazolidine-2,4-dione 1g (0.008538 mol), 4-Methoxy-benzaldehyde 1.162g, Piperidine 0.422ml, Acetic acid, and 20 ml of toluene were mixed in a dean-stark apparatus at 80 ° C, After reacting for 12 hours or longer, it was recrystallized to obtain pure 5-(4-Methoxy-benzylidene)thiazolidine-2,4-dione. Yield: 98%.
95% With C8H18NO3(1+)*C2H4NO2(1-) at 60℃; General procedure for the Knoevenagel condensation. General procedure: A mixture of carbonyl compound (0.5 mmol), activated methylene compound (0.5 mmol), IL catalyst (10 mol %) and water (1 mL) was stirred at room temperature in 25-mL round bottomed flask. Upon completion of the reaction (monitored by TLC), the reaction mixture always solidified in the round bottomed flask. Then the solidified mixture was filtered and washed with cold water (5 mL) to remove the IL catalyst, and evaporated under reduced pressure to obtain the target products. The products of 3o, 3p, 3q, 3x, 3c’, 3d’ are colourless oil, and they were purified by column chromatography on silica gel using petroleum ether/ethyl acetate as the eluent after the solvent was removed under reduced pressure. The products of 3j’, 3k’were prepared under solvent-free condition; After completion of the reaction, the solidified mixture was washed with ethanol (5 mL) to remove the IL catalyst, and evaporated under reduced pressure to obtain the target products.
93% With thiourea; urea at 110℃; for 0.166667h; Neat (no solvent); General procedure for the synthesis of 5-arylidenethiazolidine-2,4-diones and 5-arylidene-2-thioxothiazolidin-4-ones: General procedure: A mixture of aldehyde (1 mmol), 2,4-thiazolidinediones/2-thioxothiazolidin-4-ones (1 mmol) using 10 mol % urea/thiourea as catalyst was condensed at 110 °C on oil bath under solvent-free reaction conditions. After completion of the reaction as indicated by TLC, the crude product was cooled, washed with water (10 mL), filtered and recrystallization from ethanol: DMF to afford 3a-ab.
93% With SO3H and COOH functionalized pine-cone derived carbon nanoparticles In lithium hydroxide monohydrate at 25℃; for 0.133333h; Green chemistry; 3.5. General Procedure for the Synthesis of 5-arylidene-2,4-thiazolidinedione Derivatives (4a-j) General procedure: Knovenagel condensation of aromatic aldehyde (1mmol) and 2,4-thiazolidinedione (1 mmol) was performedin the presence of Pine -SO3H NPs (0.05 g) and water (5mL) as a solvent. The mixture was stirred at room temperature.Upon completion of the reaction, monitored by TLC(ethyl acetate: n-hexane 3:7), the mixture filtered off. Theproducts were purified by recrystallization from EtOH.
92% With Ce1Mg0.6Zr0.4O2 In ethanol; lithium hydroxide monohydrate at 75℃; for 1.5h;
92% With propylamino functionalized nano-structured SBA-15 In ethanol at 50℃; for 2h; General Procedure for the Preparation of 2,4-Thiazolidinediones (3h-3n) General procedure: A mixture of the aromatic aldehyde (1 mmol), 2,4-thiazolidinedione (0.133, 1 mmol) [orrhoda-nine (0.117 g, 1 mmol)] and SBA-15-Pr-NH2 (0.05 g) in EtOH (5 mL) was stirredat 50C in an oil bath for 2 hours; the progress of the reaction was monitored by TLC(2:1 n-hexane/ethyl acetate). After completion of the reaction, 10 mL acetone was addedand the mixture was filtered to remove the catalyst. Upon addition of 5 mL H2O to the filtrate,the precipitated solid obtained was collected and recrystallized from ethanol to givethe pure products, characterized by comparison of their 1H NMR spectra and meltingpoints with those reported in the literature.
92% With titanium silicate (TS-1) In lithium hydroxide monohydrate at 90℃; General reaction procedure 5-arylidene-2,4-thiazolidinediones General procedure: The condensation of 2,4-thiazolidinedione/rhodaninediones (1 mmol), with arylaldehydes (1 mmol), in the presence of a catalytic amount of TS-1 (0.04 g) in aqueous medium at 90 C was carried out by refluxing the reaction mixture for30-60 min to obtain 5-arylidene-2,4-thiazolidinediones/Rhodaninediones derivatives, as shown in Table 2, which afforded the corresponding products in excellent yields up to 92% within 30 min. Active methylene thiazolidinedione was preparedby using a reported method [41]. The progress of the reaction was monitored by thinlayer chromatography using PET ether: ethyl acetate (8:2) as a solvent system. After completion of the reaction, the reaction mixture was filtered to recover the catalystTS-1. The filtrate was concentrated to obtain crude product, which was recrystalized from hot ethanol to obtain pure product (2a-i).
91% With 1,1'-(propane-1,3-diyl)bis(3-methyl-1H-imidazol-3-ium) dibromide at 80℃; for 2h; Ionic liquid;
90% With tetra(n-butyl)ammonium hydroxide In ethanol; lithium hydroxide monohydrate at 50℃; for 1.5h; Green chemistry; General procedure for the preparation of 5-aryilidene-2,4-thiazolidinediones and 5-benzylidene rhodanines General procedure: A mixture of aromatic aldehyde (1 mmol), 2,4-thiazolidinedione or rhodanine (1 mmol) and TBAH (1 mL, 50%) were mixed in EtOH-H2O (1:1, 3 mL). The reaction mixture was stirred at 50°C in an oil bath for 1.5 h. The progress of reaction was monitored on TLC. After completion of reaction, the resulting precipitate was filtered and washed with ethanol to afford the pure product as solid in good to excellent yields. The known products were characterized by comparing the 1H NMR and melting point data with those reported in the literature.
89% With methylamine In glacial acetic acid
82% With 1-[2-(2-hydroxyethoxy)ethyl]-1,5-diazabicyclo[4.3.0]non-5-ene chloride In neat (no solvent) at 80℃; for 0.333333h; Green chemistry; General procedure for Knoevenagel condensation General procedure: A round bottom flask was charged with aryl aldehyde (10 mmol), 2,4-thiazolidinedione (10 mmol) and ionic liquid (2 mmol). The reaction mixture was stirred and monitored by TLC. Upon completion, water was added and the mixture was stirred. The mixture was allowed to stand to separate into two layers, affording the product and ionic liquid. The separated solid product was suction-filtered and further purified by crystallization from hot EtOH. The filtrate containing the ionic liquid was then evaporated under reduced pressure, and the ionic liquid was reused directly for the next run. The melting point and spectra data of products are given as below.
80% With lithium bromide for 0.133333h; Microwave irradiation; neat (no solvent);
75% With urea In neat (no solvent) for 2h; Optimization of the reaction conditions for the synthesis of5-arylidene-thiazolidine-2,4-dione derivatives General procedure: To a 25 mL flask, 50 mg of the catalyst, 1 mmol of TZDand 1 mmol of aldehyde were added. The reaction mixturewas maintained under constant agitation for 2 h at 80 C.
68% With piperidine In ethanol Reflux; Synthesis of 5-benzylidine 2, 4-thiazolidinedione (II) General procedure: Equimolar mixture of substituted benzaldehyde (20 mM)and 2,4-thiazolidinedione (20 mM) with catalytic amount ofpiperidine (1.4 g, 16 mM) and ethanol (150 mL) was refluxedcontinuously for 30-35 hours. The reaction mixturewas poured into water and filtered. On cooling, the productwas precipitated out from ethanol [36]. This step was used tosynthesize a total of ten intermediates (FP1I-FP10I).
67% With anhydrous Sodium acetate In glacial acetic acid for 0.0833333h; Microwave irradiation;
62% With piperidine; glacial acetic acid In toluene for 14h; Heating; General procedure for synthesis of (E)-5-substitutidenethiazolidine-2,4-dione) (A1-A10) General procedure: The substituted aldehydes (0.01 mol), thiazolidine-2,4-dione (0.01 mol), piperidine (0.01 mol), and acetic acid (0.01mol) were dissolved in toluene (25 ml) and heated up to Rffor azeotropic removal of water around 14 h. The mixturewas cool up to 5°C, precipitates obtained filter it, washedwith distilled water and recrystallized from appropriatesolvents to obtain pure products (A1-A10). Physical data ofthe compounds (A1-A10) are given in Table 1.
47% With 1-benzyl-4,5-dimethylimidazole 3-oxide In acetonitrile for 12h; Heating;
With anhydrous Sodium acetate; glacial acetic acid
With anhydrous Sodium acetate In glacial acetic acid
With pyridine In ethanol for 5.5h; Reflux;
With piperidine In toluene for 3h; Reflux;
With morpholine In benzene
2. Experimental General procedure: 5-Arylidene-2,4-thiazolidinediones were synthesized by Knoevenagel condensation of 2,4-thiazolidinedione (TZD) with appropriate aryl aldehydes [20].
With piperidine In toluene
With piperidine In ethanol Reflux;
With anhydrous Sodium acetate; glacial acetic acid
With piperidine at 120℃; General procedure for the synthesis of 5-(4-methylbenzylidene)-3-((1-(4-tolyl)-1H-1,2,3-triazol-4-yl)methyl)thiazolidine-2,4-dione (5a): General procedure: A mixture of thiazolidine-2,4-dione (1.0 equiv.), 4-methylbenzaldehyde (1.0 equiv.), piperidine (1.0 equiv.) and 5 mL of PEG-400 was placed in a 50 mL round-bottomed flask and the contents were stirred magnetically in an oil-bath maintained at 120 °C until 5-(4-methylbenzylidene)thiazolidine-2,4-dione (3) was formed (3-4 h), which was monitored by TLC using ethyl acetate-petroleum ether, (30:70, v/v) as eluent.
With anhydrous Sodium acetate; glacial acetic acid Reflux;
With 1-n-butyl-3-methylimidazolium tetrafluoroborate at 20℃; for 7h; Green chemistry;
With piperidine In ethanol Reflux;
With anhydrous Sodium acetate; glacial acetic acid at 110℃; for 5h;
With piperidine In ethanol for 24h; Reflux; 3.2. General Procedure for the Synthesis of 2,4-Dioxothiazolidine Acid Derivatives General procedure: 2,4-Dioxothiazolidine acid derivatives were prepared in three steps following the reportedmethod [35,40]. A solution of previously prepared TZD 1 was treated with various appropriatealdehydes via refluxing in ethanol for 24 h in the presence of piperidine as a catalyst. The reactionmixture was poured into water, followed by acidification with acetic acid to aord compounds 2a-g.Then a mixture of 2a-g (1 mmol) and ethyl 2-bromoacetate (2 mmol) was refluxed for 24 h in acetonein the presence of potassium carbonate (2 mmol) to furnish the target product as a white solid afterevaporation of the solvent. The crude product was used directly in the next step for the preparation ofthe free carboxylic acid derivatives 3a-g, where the solid product was refluxed with glacial acetic acidand HCl at a ratio of 4:1 for 2 h to aord the pure (2,4-dioxothiazolidine-3-yl)-acetic acid derivatives3a-g after evaporation of the solvents and crystallization with ethanol. The spectral data for 3a,3f, and 3g are in good agreement with previously reported ones [7,13,15] and other spectra in theSupplementary Materials.
With piperidine In ethanol for 24h; Reflux;
With piperidine In toluene at 110℃; Synthesis of 5-substituted-2,4-thiazolidinedione(5a-j) General procedure: Substituted benzaldehyde (0.1 mol) [3a-j] was added to 2,4-thiazolidinedione (0.1 mol) in toluene in the presence of piperidine and refluxed at 110 C for 6-7 h and then cooled to room temperature to precipitate out the corresponding TZD derivatives (5a-j). TLC (ethylacetate: n-hexane, 6:4)was used for verifying the improvement of the process.
With sodium hydroxide In ethanol; lithium hydroxide monohydrate
With anhydrous Sodium acetate; glacial acetic acid
With piperidine In ethanol for 10h; Reflux;
With anhydrous Sodium acetate; glacial acetic acid for 3h; Reflux;

Reference: [1]Current Patent Assignee: CHOSUN UNIVERSITY - KR2016/126772, 2016, A Location in patent: Paragraph 0248-0253
[2]Xu, Hao; Pan, Liyang; Fang, Xiaomin; Liu, Baoying; Zhang, Wenkai; Lu, Minghua; Xu, Yuanqing; Ding, Tao; Chang, Haibo [Tetrahedron Letters, 2017, vol. 58, # 24, p. 2360 - 2365]
[3]Location in patent: experimental part Shah, Sakshi; Singh, Baldev [Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 17, p. 5388 - 5391]
[4]Ghorbani, Fatemeh; Pourmousavi, Seied Ali; Kiyani, Hamzeh [Letters in Organic Chemistry, 2021, vol. 18, # 1, p. 66 - 81]
[5]Rathod, Sandip; Navgire, Madhukar; Arbad, Balasaheb; Lande, MacHhindra [South African Journal of Chemistry, 2012, vol. 65, p. 196 - 201]
[6]Veisi, Hojat; Naeimi, Alireza; Maleki, Behrooz; Ashrafi, Samaneh Sedigh; Sedrpoushan, Alireza [Organic Preparations and Procedures International, 2015, vol. 47, # 4, p. 1 - 7]
[7]Gadekar, Sachin P.; Dipake, Sudarshan S.; Gaikwad, Suresh T.; Lande, Machhindra K. [Research on Chemical Intermediates, 2018, vol. 44, # 12, p. 7509 - 7518]
[8]Location in patent: experimental part Jawale, Dhanaji V.; Pratap, Umesh R.; Lingampalle, Dinesh L.; Mane, Ramrao A [Chinese Journal of Chemistry, 2011, vol. 29, # 5, p. 942 - 946]
[9]Khazaei, Ardeshir; Veisi, Hojat; Safaei, Maryam; Ahmadian, Hossein [Journal of Sulfur Chemistry, 2014, vol. 35, # 3, p. 270 - 278]
[10]Levshin, I. B.; Tsurkan, A. A.; V'yunov, K. A.; Ginak, A. I. [Journal of applied chemistry of the USSR, 1983, vol. 56, # 7, p. 1361 - 1362][Zhurnal Prikladnoi Khimii (Sankt-Peterburg, Russian Federation), 1983, vol. 56, # 7, p. 1453 - 1455]
[11]Liu, Yuting; Li, Rong; Xing, Yanjun [Heterocycles, 2015, vol. 91, # 7, p. 1385 - 1397]
[12]Location in patent: experimental part Saini, Anil; Bhatti, Ravinder S.; Sandhu, Jagir S. [Journal of the Indian Chemical Society, 2007, vol. 84, # 12, p. 1239 - 1241]
[13]De Paiva, Raíssa K.C.; Da Silva, Jamerson F.; Moreira, Hudieyllen A.; Pinto, Osvaldo G.; Camargo, Lilian T.F.M.; Naves, Plínio L.F.; Camargo, Ademir J.; Ribeiro, Luciano; Ramos, Luciana M. [Journal of the Brazilian Chemical Society, 2019, vol. 30, # 1, p. 164 - 172]
[14]Mishra, Garima; Sachan, Narsingh; Chawla, Pooja [Letters in Organic Chemistry, 2015, vol. 12, # 6, p. 429 - 445]
[15]Fazylov; Nurkenov; Amerkhanova, Sh. K.; Tolepbek [Russian Journal of General Chemistry, 2013, vol. 83, # 9, p. 1792 - 1793][Zh. Obshch. Khim., 2013, vol. 83, # 9, p. 1577 - 1578,2]
[16]Patel, Jaydeep A.; Patel, Navin B.; Tople, Manesh S. [Indian Journal of Heterocyclic Chemistry, 2021, vol. 31, # 3, p. 379 - 387]
[17]Mityanov, Vitaly S.; Kutasevich, Anton V.; Krayushkin, Michail M.; Lichitsky, Boris V.; Dudinov, Arkady A.; Komogortsev, Andrey N.; Koldaeva, Tatyana Yu.; Perevalov, Valery P. [Tetrahedron, 2017, vol. 73, # 47, p. 6669 - 6675]
[18]Lo et al. [Journal of the American Chemical Society, 1953, vol. 75, p. 4845]
[19]V'yunov,K.A. et al. [Journal of Organic Chemistry USSR (English Translation), 1971, vol. 7, p. 1799 - 1802][Zhurnal Organicheskoi Khimii, 1971, vol. 7, # 8, p. 1733 - 1736]
[20]Location in patent: experimental part Akbari; Tala; Dhaduk; Joshi; Mehta; Pathak [Phosphorus, Sulfur and Silicon and the Related Elements, 2008, vol. 183, # 6, p. 1471 - 1477]
[21]Location in patent: scheme or table Murugan, Ramalingam; Anbazhagan; Sriman Narayanan [European Journal of Medicinal Chemistry, 2009, vol. 44, # 8, p. 3272 - 3279]
[22]Location in patent: scheme or table Popov-Pergal, Katarina M.; Poleti, Dejan; Rancic, Milica P.; Meden, Antun; Pergal, Marija V. [Journal of Heterocyclic Chemistry, 2010, vol. 47, # 1, p. 224 - 228]
[23]Location in patent: experimental part Rančić, Milica; Trišović, Nemanja; Milčić, Miloš; Ušćumlić, Gordana; Marinković, Aleksandar [Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2012, vol. 86, p. 500 - 507]
[24]Pattan, Shashikant; Kedar, Manisha; Pattan, Jayashri; Dengale, Santosh; Sanap, Manjusha; Gharate, Utkarsha; Shinde, Punam; Kadam, Sushma [Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2012, vol. 51, # 9, p. 1421 - 1425]
[25]Sonawane, Lalit V.; Bari, Sanjaykumar B. [Indian Journal of Heterocyclic Chemistry, 2010, vol. 20, # 2, p. 167 - 168]
[26]Stana, Anca; Tiperciuc, Brindusa; Duma, Mihaela; Pirnau, Adrian; Verite, Philippe; Oniga, Ovidiu [Journal of the Serbian Chemical Society, 2014, vol. 79, # 2, p. 115 - 123]
[27]Sindhu, Jayant; Singh, Harjinder; Khurana; Sharma, Chetan; Aneja [Chinese Chemical Letters, 2015, vol. 26, # 1, p. 50 - 54]
[28]Khan, Firoz A. Kalam; Patil, Rajendra H.; Shinde, Devanand B.; Sangshetti, Jaiprakash N. [Chemical Biology and Drug Design, 2016, vol. 88, # 6, p. 938 - 944]
[29]Kommidi, Devendar Reddy; Pagadala, Ramakanth; Varkolu, Mohan; Koorbanally, Neil A.; Moodley, Brenda [Journal of Heterocyclic Chemistry, 2017, vol. 54, # 2, p. 1071 - 1076]
[30]Metwally, Kamel; Pratsinis, Harris; Kletsas, Dimitris [European Journal of Medicinal Chemistry, 2017, vol. 133, p. 340 - 350]
[31]Hassan, Ghaneya S.; Georgey, Hanan H.; Mohammed, Esraa Z.; Omar, Farghaly A. [European Journal of Medicinal Chemistry, 2019, vol. 184]
[32]Alhameed, Rakia Abd; Almarhoon, Zainab; Bukhari, Sarah I.; El-Faham, Ayman; De La Torre, Beatriz G.; Albericio, Fernando [Molecules, 2020, vol. 25, # 1]
[33]Alhameed, Rakia Abd; Almarhoon, Zainab; Berrino, Emanuela; El-Faham, Ayman; Supuran, Claudiu T. [Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, vol. 35, # 1, p. 549 - 554]
[34]Sujatha, Bogiri; Chennamsetty, Subramanyam; Chintha, Venkataramaiah; Wudayagiri, Rajendra; Prasada Rao, Kammela [Phosphorus, Sulfur and Silicon and the Related Elements, 2020, vol. 195, # 7, p. 586 - 591]
[35]Alam, Mohammad Mahboob; Alzhrani, Zohor Mohammad Mahdi; Nazreen, Syed; Neamatallah, Thikryat [Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, vol. 35, # 1, p. 1116 - 1123]
[36]El-Adl, Khaled; Sakr, Helmy; Nasser, Mohamed; Alswah, Mohamed; Shoman, Fatma M. A. [Archiv der Pharmazie, 2020, vol. 353, # 9]
[37]El-Zahabi, Mohamed Ayman; Sakr, Helmy; El-Adl, Khaled.; Zayed, Mohamed; Abdelraheem, Adel S.; Eissa, Sally I.; Elkady, Hazem; Eissa, Ibrahim H. [Bioorganic Chemistry, 2020, vol. 104]
[38]Abdel-Aziz, Hatem A.; Abdelrahman, Mohamed A.; Afarinkia, Kamyar; Al-Warhi, Tarfah; Aljaeed, Nada; Alotaibi, Ohoud J.; Elbadawi, Mostafa M.; Eldehna, Wagdy M.; Elimam, Diaaeldin M.; Mahdy, Hazem A.; Nocentini, Alessio; Supuran, Claudiu T.; Taghour, Mohammed S. [Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, vol. 37, # 1, p. 531 - 541]
  • 2
  • [ 6320-51-0 ]
  • [ 613-54-7 ]
  • [ 1623092-96-5 ]
YieldReaction ConditionsOperation in experiment
81% Stage #1: 5-(4-methoxybenzylidene)thiazolidine-2,4-dione With potassium hydroxide In N,N-dimethyl-formamide at 20℃; for 0.5h; Stage #2: 2-Bromo-2'-acetonaphthone at 20℃; for 8h; General procedure: To a solutionof 4 (235 mg, 1 mmol) in DMF (3.5 mL) was added finely dispersed anhydrous potassium hydroxide (84 mg, 1.5 mmol). The mixture was stirred for 30 min at room temperatureto give the potassium salt of 5-(4-methoxybenzylidene)thiazolidine-2,4-dione. To the resulting suspension was added 2-bromo-1-phenylethanone (199 mg, 1 mmol) and then the reaction mixture was stirred at room temperature for 8 h. TLC was used to monitor the reaction progress. After completion of the reaction, the mass was poured into ice-cold water under continuous stirring. The resulting compound was washed with water and ethanol, dried andthen recrystallized from absolute ethanol. White solid; yield: 79 %.
  • 3
  • [ 6320-51-0 ]
  • [ 29310-88-1 ]
  • 5-(4-methoxybenzylidene)-3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione [ No CAS ]
YieldReaction ConditionsOperation in experiment
85% With potassium carbonate; potassium iodide In N,N-dimethyl-formamide for 8h; Reflux;
74% With potassium carbonate In N,N-dimethyl-formamide Microwave irradiation; General Method for the Synthesis of 5-benzylidene-3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione derivatives (FP1-FP10) General procedure: A mixture of 5- benzylidene thiazolidine-2,4-dione derivative(2 mM), brominated coumarin (3 mM), potassiumcarbonate (0.5 g) and DMF (5 mL) in a 100 mL round bottomflask was heated in a modified microwave oven (420 W)for appropriate time and reaction was monitored by TLC.After cooling, the reaction mixture was poured into waterand the crude product was filtered out and recrystallizedfrom acetone [38].
  • 4
  • [ 6320-51-0 ]
  • [ 587-65-5 ]
  • 2-(5-(4-methoxybenzylidene)-2,4-dioxothiazolidine-3-yl)-N-phenylacetamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
88% Stage #1: 5-(4-methoxybenzylidene)thiazolidine-2,4-dione With potassium carbonate In N,N-dimethyl-formamide at 100℃; for 0.5h; Stage #2: N-chloroacetyl-aniline In N,N-dimethyl-formamide at 100℃; for 24h; 4.1.1. 2-(5-Un/substitutedbenzylidene-2,4-dioxothiazolidin-3-yl)-N-un/substitutedphenyl acetamide 4a-f, 5a-f, 6a-f General procedure: A solution of the appropriate benzylidene thiazolidindione (2af)(10 mmol) and anhydrous potassium carbonate (0.69 g, 5 mmol)in dry DMF (20 mL), was stirred at 100 °C for 30 min. The corresponding2-chloro N-un/sub phenyl acetamide (3a-c) (10 mmol)was added and stirring was continued at 100 °C for 24 h. The reaction mixture was poured onto crushed ice, the precipitated product was filtered off, dried and crystallized from ethanol.
  • 5
  • [ 6320-51-0 ]
  • [ 3289-75-6 ]
  • 2-(5-(4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl)-N-(4-chlorophenyl)acetamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
89% Stage #1: 5-(4-methoxybenzylidene)thiazolidine-2,4-dione With potassium carbonate In N,N-dimethyl-formamide at 100℃; for 0.5h; Stage #2: 2-chloro-N-(4-chlorophenyl)acetamide In N,N-dimethyl-formamide at 100℃; for 24h; 4.1.1. 2-(5-Un/substitutedbenzylidene-2,4-dioxothiazolidin-3-yl)-N-un/substitutedphenyl acetamide 4a-f, 5a-f, 6a-f General procedure: A solution of the appropriate benzylidene thiazolidindione (2af)(10 mmol) and anhydrous potassium carbonate (0.69 g, 5 mmol)in dry DMF (20 mL), was stirred at 100 °C for 30 min. The corresponding2-chloro N-un/sub phenyl acetamide (3a-c) (10 mmol)was added and stirring was continued at 100 °C for 24 h. The reaction mixture was poured onto crushed ice, the precipitated product was filtered off, dried and crystallized from ethanol.
Same Skeleton Products
Historical Records